Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co (SZSE:300937) YoY Rev. per Sh. Growth : 10.47% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 was 10.47%.

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥12.93.

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co YoY Rev. per Sh. Growth Historical Data

The historical data trend for Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co YoY Rev. per Sh. Growth Chart

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY Rev. per Sh. Growth

Get a 7-Day Free Trial

8.58

21.58

-3.99

11.76

11.00

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY Rev. per Sh. Growth	Get a 7-Day Free Trial															17.52	22.39	7.51	2.29	10.47

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY Rev. per Sh. Growth (A: Dec. 2023 )
=	(Revenue per Share (A: Dec. 2023 )	-	Revenue per Share (A: Dec. 2022 ))	/	\| Revenue per Share (A: Dec. 2022 ) \|
=	(46.141	-	41.567)	/	\| 41.567 \|
=	11.00 %

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's YoY Rev. per Sh. Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY Rev. per Sh. Growth (Q: Mar. 2024 )
=	(Revenue per Share (Q: Mar. 2024 )	-	Revenue per Share (Q: Mar. 2023 ))	/	\| Revenue per Share (Q: Mar. 2023 )) \|
=	(12.93	-	11.705)	/	\| 11.705 \|
=	10.47 %

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co (SZSE:300937) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd (SZSE:300937) » Definitions » YoY Rev. per Sh. Growth

Traded in Other Exchanges

N/A

Address

No. 18, Youlian 1st Street, 13th Floor, Jinniu District, Sichuan Province, Chengdu, CHN, 610081

Website

https://www.hezongyy.com

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co Ltd provides convenient, efficient and low-cost medical circulation services for the vast community medical terminals and primary medical institutions. It offers various products such as respiratory system, cardiovascular and neurological drugs, biological product, rheumatism and bone injuries and other medicines, cardiovascular and neurological drugs and others.

Executives

Tian Wen Shu	Supervisors
Ai Ying Ping	Director
Lei Qi Gang	Executives
Hao Rui Zhi	Directors, Directors, and Executives

Sinchuan Hezong Medicine Easy-to-buy Pharmaceutical Co (SZSE:300937) Headlines

No Headlines